Non-infectious systemic diseases and uveitis;Enfermedades sistémicas no infecciosas y uveítis

Anales del Sistema Sanitario de Navarra

Volumn 31, Issue SUPPL. 3, 2008, Pages 97-110

  Diaz Valle D ^a   Mendez R ^a   Arriola, P ^a   Cuina R ^a   Arino M ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Beh et disease; Multiple sclerosis; Sarcoidosis; Uveitis; Vogt koyanagi harada syndrome

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN A; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE;

BEHCET DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE ASSOCIATION; EYE INJURY; HUMAN; MORBIDITY; MULTIPLE SCLEROSIS; REVIEW; SARCOIDOSIS; UVEITIS; VOGT KOYANAGI SYNDROME; WEGENER GRANULOMATOSIS;

BEHCET SYNDROME; HUMANS; MULTIPLE SCLEROSIS; SARCOIDOSIS; UVEITIS; UVEOMENINGOENCEPHALITIC SYNDROME;

EID: 63849188587     PISSN: 11376627     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. FERNANDEZ ESPARTERO MC, ALEJANDRE N, DIAZ-VALLE D. Sarcoidosis. En DIAZ-VALLE D, MÉNDEZ R, BENITEZ DEL CASTILLO JM. Actualización en el tratamiento de las uveitis. Ed. Sociedad Espanola de Oftalmologia. Madrid 2007; 123-130.
2. CRYSTAL R. Sarcoidosis. En Harrison. Principios de Medicina Interna. Ed. Mc Graw-Hill:1994; 1932-1938.
3. MANA M. Sarcoidosis. Med Clin (Barc) 2001; 116:307-311.
4. JABS DA, JOHNS CJ. Ocular involvement in chronic sarcoidosis. Am J Ophthalmol 1986; 102:297-301.
5. ADAN A, BAGET M, LLOBET JM, SEGURA A, MARIEGES MT, CASAROLI-MARANO R. Uveitis como manifestacion inicial de sarcoidosis. Estudio de 31 pacientes. Med Clin (Barc) 2004; 122:748-752.
6. ABAD S, MEYSSONIER V, ALLALI J, GOUYA H, GIRAUDET AL, MONNET D et al. Association of peripheral multifocal choroiditis with sarcoidosis:a study of thirty-seven patients. Arthritis Rheum 2004; 51:974-982.
7. POWER WJ, NEVES RA, RODRIGUEZ A, PEDROZA-SERES M, FOSTER CS. The value of combined serum angiotensina converting enzyme and gallium scan in the diagnosis of sarcoidosis. Ophthalmology 1995; 102:2007-2012.
8. DEV S, MCCALUUM RM, JAFFE GJ. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 1999 106:111-118.
9. PRITCHARD C, NADARAJAH K. Tumour necrosis factor-alpha inhibitor treatment for sarcoidosis refractory to convenctional treatments. A reporto f five patients. Ann Rheum Dis 2004; 63:318-320.
10. VOGT A. Fruhzeitiges Ergaruen der Zilien und Bemerkungen uber den sogenaten plotzlichen Eintreitt dieser Veranderung.Klin Monatsbl Augenheilkd 1906;44:228-242.
11. KOYANAGI Y. Dysakusis, alopecia und poliosis bei schwerer uveitis nicht traumatischen Ursprugs. Klin Monatsbl Augenheilkd 1929; 82:194-211.
12. HARADA E. Acute diffuse choroiditis. Acta Soc Ophthalmol Jpn 1926;30:356-378.
13. 13.READ RW, HOLLAND GN, RAO NA, TABBARA KF, OHNO S, ARELLANES-GARCIA L et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease:report of an international committee on nomenclature. Am J Ophthalmol 2001; 131:647-652.
14. ANDREOLI CM, FOSTER CS. Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin 2006; 46:111-122.
15. BOUCHENAKI N, HERBORT CP. The contribution of indocyanine green angiography to the appraisal and management of Vogt-Koyanagi-Harada disease. Ophthalmology 2001;108:54-64.
16. BOUCHENAKI N, MORISOD L, HERBORT CP. Vogt-Koyanagi-Harada syndrome:importance of rapid diagnosis and therapeutic intervention. Klin Monatsbl Augenheilkd 2000;216:290-294.
17. BYKHOVSKAYA I, THORNE JE, KEMPEN JH, DUNN JP, JABS DA. Vogt-Koyanagi-Harada disease:Clinical Outcomes. Am J Ophthalmol 2005; 140:674-678.
18. YAMANAKA E, OHGURO N, YAMAMOTO S, NAKAGAWA Y, IMOTO Y, TANO Y. Evaluation of pulse corticosteroid therapy for Vogt-Koyanagi-Harada disease assessed by optical coherence tomography. Am J Ophthalmol 2002;134:454-456.
19. LAI TY, CHAN RP, CHAN CK, LAM DS. Effects of the duration of initial oral corticosteroid treatment on the recurrence of inlamation in Vogt-Koyanagi-Harada disease. Eye 2008, Mar 28. [Epub ahead of print]
20. SASAMOTO Y, OHNO S, MATSUDA H. Studies on corticosteroid therapy in Vogt-Koyanagi-Harada disease. Ophthalmologica 1990;201:162-167.
21. RUBSAMEN PE, GASS JD:Vogt-Koyanagi-Harada syndrome. Clinical course, therapy and long-term visual outcome. Arch Ophthalmol 1991; 109:682-687.
22. RAJENDRAM R, EVANS M, RAO NA. Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin 2005; 45:115-134.
23. ANDRADE RE, MUCCIOLI C, FARAH ME, NUSSENBLATT RB, BELFORT R JR. Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 2004;137:572-574.
24. KIM SJ, YU HG. The use of low-dose azathioprine in patients with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 2007; 15:381-387.
25. PAREDES I, AHMED M, FOSTER CS. Immunomodulatory therapy for VKH patients as first line therapy. Ocul Immunol Inflamm 2006;14:87-90.
26. KAHN P, WEISS M, IMUNDO LF, LEVY DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006;113:860-864.
27. DÍAZ LLOPIS M, AMSELEM L, ROMERO FJ, GARCÍA-DELPECH S, HERNÁNDEZ ML. Adalimumab therapy for Vogt-Koyanagi-Harada syndrome. Arch Soc Esp Oftalmol 2007; 82:131-132.
28. HAFLER DA, SLAVIK JM, ANDERSON DE, O'CONNOR KC, DE JAGER P, BEACHER-ALLAN C. Multiple sclerosis. Immunol Rev 2005; 204:208-231.
29. RUGGIERI M, IANNETTI P, POLIZZI A, PAVONE L, GRIMALDI LM, Italian Society of Paediatric Neurology Study Group on Childhood Multiple Sclerosis. Multiple sclerosis in children under 10 years of age. Neurol Sci 2004; 25 (Suppl 4):S326-S335.
30. JACOBS DA, GALETTA SL. Multiple sclerosis and the visual system. Ophthalmol Clin North Am 2004; 17:265-273.
31. FROHMAN EM, FROHMAN TC, ZEE DS, et al. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 2005; 4:111-121.
32. TOWLER HM, LIGHTMAN S. Symptomatic intraocular inflammation in multiple sclerosis. Clin Experiment Ophthalmol 2000; 28:97-102.
33. PATTE M, ROUHER FN, VERNAY D, DELAIRE JC, BACIN F. Proliferative retinal vasculitis and multiple sclerosis:a case report. J Fr Ophtalmol 2003; 26:381-385.
34. SMITH JR, ROSENBAUM JT. Neurological concomitants of uveitis. Br J Ophthalmol 2004; 88:1498-1499.
35. ZEIN G, BERTA A, FOSTER CS. Multiple sclerosis-associated uveitis. Ocul Immunol Inflamm 2004; 12:137-142.
36. BIOUSSE V, TRICHET C, BLOCH-MICHEL E, ROULLET E. Multiple sclerosis associated with uveitis in two large clinic-based series. Neurology 1999; 52:179-181.
37. International Study Group for Behçet's disease. Criteria for diagnosis of Behçet disease. Lancet 1990; 335:1078-1080.
38. SUZUKI KUROKAWA M, SUZUKI N. Behcet's disease. Clin Exp Med. 2004; 4:10-20.
39. YAZICI H, TUZUN Y, PAZARLI H, YURDAKUL S, OZYAZGAN, OZDOGAN H et al. Influence of age of onset and patient's sex on prevalence and severity of manifestations of Behcet's syndrome, Ann Rheum Dis 1984; 43:783-789.
40. DÍAZ LLOPIS M, SALOM ALONSO D et al. Enfermedad de Behcet. DÍAZ-VALLE D, MÉNDEZ FERNÁNDEZ R, BENITEZ DEL CASTILLO JM. Actualización en el tratamiento de las uveítis. Madrid. Sociedad Española de Oftalmología. 2007:113-122.
41. ZAFIRAKIS P:Adamantiades-Behget Disease. En:Foster CS, Vitale AT. Diagnosis and Treatment of Uveitis. Philadelphia, PA:W.B. Saunders Co; 2002; 632-652.
42. VERITY DH, WALLACE GR, VAUGHAN RW, STANFORD MR. Behçet's disease:from Hippocrates to the third millennium, Br J Ophthalmol 2003; 87:1175-1183.
43. KAÇMAZ RO, KEMPEN JH, NEWCOMB C, GANGAPUTRA S, DANIEL E, LEVY-CLARKE GA et al. Ocular inflammation in Behçet disease:incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol 2008 Aug. 15 [Epud ahead of print].
44. OHNO S, NAKAMURA S. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004; 31:1362-1368.
45. SFIKAKIS PP, KAKLAMANIS PH. Infliximab for recurrent, sightthreatening ocular inflammation in Adamantiades-Behcetdisease. Ann intern Med 2004; 140:404-406.
46. TESSLER HH, JENNINGS T. High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behcet's disease. Br J Ophthalmol 1990; 74:353-357.
47. ADÁN A, NAVARRO M, CASAROLI- MARANO RP, ORTIZ S, MOLINA JJ. Intravitreal bevacizumab as initial treatment for choroidal neovascularization associated with presumed ocular histoplasmosis syndrome. Graefes Arch Clin Exp Ophthalmol 2007; 245:1873-1875.
48. MONDÉJAR JJ, DÍAZ-LLOPIS M. Lupus Eritematoso. En:Sánchez Salorio M, Díaz-Llopis M, Benítez del Castillo JM, Rodríguez Ares MT. Manifestaciones oftalmológicas de las enfermedades generales. Madrid; Sociedad Española de Oftalmoloǵia; 2001:69-72.
49. DÍAZ-VALLE D, SANTOS BUESO E, MÍGUELES SANCHEZ R, DÍAZ-VALLE T. Vasculitis retiniana. En Díaz-Valle D, Méndez Fernández R, Benítez del Castillo JM. Actualización en el tratamiento de las uveítis. Madrid; Sociedad Española de Oftalmología; 2007:141-148.
50. GHARBIYA M, BOZZONI-PANTALEONI F, AUGELLO F, BALACCO-GABRIELI C. Indocyanine green angiographic findings in systemic lupus erythematosus choroidopathy. Am J ophthalmol 2002; 134:286-290.
51. NUSSENBLATT RB. Retinal Vasculitis. NUSENBLATT RB, WHITCUP SM. Uveitis. Philadelphia, Pennsylvania, USA;Mosby; 2004:372-383.
52. MONDÉJAR JJ, DÍAZ-LLOPIS M. Granulomatosis de Wegener. En:Sánchez Salorio M, Díaz-Llopis M, Benítez del Castillo JM, Rodríguez Ares MT. Manifestaciones oftalmológicas de las enfermedades generales. Madrid; Sociedad Española de Oftalmología; 2001:67-69.
53. HUONG DU LT, TRAN TH, PIETTE JC. Granulomatous uveitis revealing Wegener's granulomatosis. J Rheumatol 2006; 33:1209-1210.
54. BULLEN CL, LIESEGANG TJ, MCDONALD TJ, DEREMEE RA. Ocular complications of Wegener's granulomatosis. Ophthalmology 1983; 90:279-290.